PDGFRb Modulators Target Mutant p53 Tumor Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mutant p53 proteins contribute to tumor invasion and metastasis by disrupting the p73/NF-Y complex, leading to the upregulation of PDGFRb, which is not effectively targeted by existing cancer therapies, particularly in pancreatic, colorectal, and ovarian cancers.
Innovation Solution
Development of PDGFRb modulators, such as activators or inhibitors, to target the platelet-derived growth factor receptor beta (PDGFRb) in tumors with mutant p53 mutations, thereby modulating metastasis and providing a therapeutic approach for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cancer therapies are used, then general tumor treatment is achieved, but mutant p53-induced PDGFRb upregulation and metastasis are not effectively targeted
Solution Approach 1:
The patent applies local quality by developing PDGFRb-specific modulators that target the unique molecular characteristic induced by mutant p53. Instead of using general cancer therapies, the invention creates a specialized treatment that addresses the specific PDGFRb upregulation pathway activated by mutant p53, thereby improving treatment effectiveness for this particular molecular subtype while maintaining selectivity.
Solution Approach 2:
The patent inverts the conventional approach by not directly targeting mutant p53 itself, but rather targeting the downstream consequence (PDGFRb upregulation) that results from mutant p53 activity. This indirect targeting strategy allows therapies to address the functional outcome of mutant p53 without needing to directly inhibit the mutant protein, thereby achieving effective treatment where direct p53 targeting has failed.
2Reliability
If PDGFRb modulators are used to target mutant p53-induced metastasis, then metastasis inhibition is achieved, but the complexity of identifying and developing such agents increases
Solution Approach 1:
The patent applies preliminary action by first identifying and characterizing the PDGFRb upregulation mechanism as a specific biomarker for mutant p53-driven metastasis. This preliminary characterization creates a clear target definition and validation framework that simplifies subsequent drug development efforts, allowing researchers to focus on developing PDGFRb modulators with known mechanisms and validated targets, thereby reducing overall development complexity.
Data Source
Figure 1A~1C
Figure 2A~2E
Figure 3A~3E
AI summary
PDGFRb inhibitors and the use of such inhibitors to treat mutant p53-expressing tumors are described.